Highest-materiality recent filing
Novanta shareholders elect all nine directors and approve executive compensation at annual meeting
All nine director nominees elected; votes for ranged from 30.98M to 31.74M.
Novanta enters $200M delayed draw term loan facility maturing 2030
Second Amendment to Credit Agreement establishes $200M delayed draw term loan commitments.
Novanta Q1 revenue up 10% to $258M, adjusted EPS $0.81, net income $21M
GAAP revenue $257.7M (+10% YoY); GAAP net income $21.1M (flat).
Novanta Q4 revenue $258M (+9% YoY), adjusted EPS $0.91 (+20% YoY)
GAAP revenue $258.3M in Q4 2025, up 9% YoY; GAAP diluted EPS $0.45.
Novanta appoints Alexander Manganiello as General Counsel and Corporate Secretary
Appointed Alexander Manganiello as General Counsel and Corporate Secretary effective December 1, 2025.
Novanta revises Q4 and FY 2025 adjusted EPS guidance lower after equity issuance
Q4 2025 non-GAAP adjusted diluted EPS now $0.84-$0.91 (prior $0.87-$0.93).
Novanta closes $632.5M tangible equity units offering; amends credit agreement
Issued 12,650,000 Units at $50.00 each, including full over-allotment exercise.
Novanta Q3 2025 revenue up 1.4% to $247.8M; GAAP EPS drops to $0.30 from $0.53
GAAP revenue $247.8M (+1.4% YoY); GAAP net income $10.7M vs $19.2M in Q3 2024.
Novanta board authorizes additional $200M share repurchase; total capacity $231M
Board approved $200M additional common share repurchase authorization on Sept 17, 2025.
Novanta director Barbara Hulit resigns from board, effective Nov 1, 2025
Barbara Hulit resigned from Novanta's Board, effective November 1, 2025.
Novanta Q2 2025 GAAP EPS falls 68% to $0.12; Adj. EPS rises to $0.76 on 2% revenue growth
GAAP revenue $241.0M (+2% YoY); GAAP net income $4.5M vs $13.8M; GAAP diluted EPS $0.12 vs $0.38.
Novanta General Counsel & Corporate Secretary Michele D. Welsh to depart July 18, 2025
Michele D. Welsh will no longer serve as General Counsel and Corporate Secretary effective July 18, 2025, or earlier if mutually agreed.
Novanta enters $1.0B credit facility maturing 2030; replaces $392.4M existing debt
Facility includes €65.31M euro term loan, $75M US term loan, $850M revolver; maturity June 2030.
Novanta announces restructuring plan with $20M-$25M pre-tax charges
Pre-tax charges estimated at $20M-$25M from employee-related costs, manufacturing moves, contract terminations, and asset write-offs.
Novanta holds annual meeting; all director nominees elected, advisory votes approved
All nine director nominees elected with substantial support (each received >31M votes for).
Novanta Q1 rev +1% to $233M; GAAP NI +45%; adj EPS flat $0.74
GAAP revenue $233.4M (+1% YoY); GAAP net income $21.2M (+45%); GAAP diluted EPS $0.59 vs $0.41.
Novanta Reports Q4 and Full Year 2024 Results: Revenue Up 13% in Q4, 8% for Full Year
Q4 2024 revenue increased 13% to $238M; GAAP diluted EPS $0.46, adjusted EPS $0.76.
Novanta recasts segment reporting into Automation Enabling Technologies and Medical Solutions
Two new segments replace prior three-segment structure (Precision Medicine & Manufacturing, Robotics & Automation, Medical Solutions).
Novanta Q3 2024 revenue up 10% to $244M; GAAP EPS $0.53 vs $0.59 a year ago
Revenue $244.4M, +10% YoY from $221.5M.
Novanta appoints John Burke as Chief Accounting Officer; Peter Chang departs after 13 years
John Burke, former VP Global Accounting, named CAO effective Aug 22, 2024, succeeding Peter Chang.
Novanta Q2 2024 revenue up 2.8% to $236M, but GAAP EPS falls 34% to $0.38
Revenue $235.9M (+2.8% YoY); GAAP net income $13.8M vs $20.9M in Q2 2023.
Novanta announces departure of CHRO Brian Young effective Nov 1, 2024
Brian Young, Chief Human Resources Officer, to leave Novanta effective Nov 1, 2024 or earlier as agreed.
Novanta director Katherine Owen resigns; Mary Kay Ladone elected to board
Katherine A. Owen resigned from board and Audit Committee on July 11, 2024, effective immediately; no disagreement cited.
Novanta shareholders approve all proposals at 2024 annual meeting
94.33% of outstanding shares (33.9M) were present or represented at the May 8, 2024 AGM.
Novanta Q1 2024 revenue up 5.4% to $231M; GAAP net income down to $14.7M
GAAP revenue $230.9M vs $219.1M YoY; GAAP net income $14.7M vs $18.3M.
Novanta replaces PwC with Deloitte as independent auditor after competitive process
Board requested PwC's resignation effective March 14, 2024, engaging Deloitte as successor.
Mr. Burke succeeds Peter Chang, Chief Accounting Officer and Corporate Controller of the Company, who departed from the role effective August 22, 2024.
On August 22, 2024, John Burke, formerly Vice President of Global Accounting for Novanta Inc. (the “Company”), was appointed Chief Accounting Officer of Novanta Inc. and assumed the role of principal accounting officer.
On August 1, 2024, Novanta Inc. (the “Company”) announced that Brian Young, Chief Human Resources Officer (“CHRO”) of the Company, would no longer serve as the CHRO, effective on November 1, 2024, or such earlier date as may be agreed between Mr. Young and determined by the Company.
On July 11, 2024, Katherine A. Owen resigned as a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”) and the Audit Committee of the Board, effective immediately.
On July 11, 2024, the Board elected Mary Katherine (Mary Kay) Ladone to the Board to fill the vacancy created by Ms. Owen’s resignation, effective July 11, 2024.
Max materiality 0.90 · Median 0.50 · Most common event earnings